1Menard C, Johann D, Lowenthal M, et al. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis[J]. Cancer Res, 2006,66:1844-1850.
2Watt SA, Patschkowski T, Kalinowski J, et al. Qualitative and quantitative proteomics by two-dimensional gel electrophoresis, peptide mass fingerprint and a chemically coded affinity tag (CCAT)[J]. J Biotechnol, 2003,106:287-300.
3Mocellin S, Rossi CR, Traldi P, et al, Molecular oncology in the post-genomic era: the challenge of proteomics[J].Trends Mol Med, 2004,10(1):24-32.
4Moscova M, Marsh DJ, Baxter RC. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines [J]. Cancer Res,2006,66:1376-1383.
5Alessandro R, Fontana S, Kohn E, et al. Proteomic strategies and their application in cancer research[J]. Tumori, 2005,91:447-455.
6Liu Y. Serum proteomic pattern analysis for early cancer detection[J]. Technol Cancer Res Treat, 2006,5:61-66.
7Lee WC, Lee KH. Applications of affinity chromatography inproteomics[J]. Anal Biochem, 2004,324:1-10.
8Comunale MA, Lowman M, Long RE, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma[J].J Proteome Res, 2006,5:308-315.
9Gabriele L, Moretti F, Pierotti MA, et al. The use of microarray technologies in clinical oncology[J].J Transl Med, 2006,4:8-15.
10Weinstein MH, O'Leary MP, Richie JP, et al. Prostate carcinoma tissue proteomics for biomarker discovery[J]. Cancer,2003,98:2576-2582.
